John C. Michalak

2.5k total citations
24 papers, 1.9k citations indexed

About

John C. Michalak is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, John C. Michalak has authored 24 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in John C. Michalak's work include Cancer Treatment and Pharmacology (4 papers), Chronic Lymphocytic Leukemia Research (2 papers) and CAR-T cell therapy research (2 papers). John C. Michalak is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Chronic Lymphocytic Leukemia Research (2 papers) and CAR-T cell therapy research (2 papers). John C. Michalak collaborates with scholars based in United States and Canada. John C. Michalak's co-authors include Charles L. Loprinzi, Paul J. Novotny, Jeff A. Sloan, Judith R. OʼFallon, Gamini S. Soori, Susan K. Quella, Alan K. Hatfield, Philip J. Stella, Raylene M. Rospond and Ann Marie Dose and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

John C. Michalak

24 papers receiving 1.8k citations

Peers

Countries citing papers authored by John C. Michalak

Since Specialization

Citations

This map shows the geographic impact of John C. Michalak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Michalak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Michalak more than expected).

Fields of papers citing papers by John C. Michalak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Michalak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Michalak. The network helps show where John C. Michalak may publish in the future.

Co-authorship network of co-authors of John C. Michalak

This figure shows the co-authorship network connecting the top 25 collaborators of John C. Michalak. A scholar is included among the top collaborators of John C. Michalak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Michalak. John C. Michalak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/− Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-α2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696 2009 ·Clinical Cancer Research ·John M. Kirkwood, Charles Lee, Stergios Moschos, Mark R. Albertini, John C. Michalak, Cindy Sander, Theresa L. Whiteside, Lisa H. Butterfield, Louis M. Weiner	103
2	Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group 2008 ·Leukemia & lymphoma ·Thomas E. Witzig, Susan M. Geyer, Paul J. Kurtin, Joseph P. Colgan, David J. Inwards, Ivana N. Micallef, Betsy LaPlant, John C. Michalak, Muhammad Salim, Robert J. Dalton, Dennis F. Moore, Craig B. Reeder	38
3	Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy 2007 ·Cancer ·Ravi D. Rao, John C. Michalak, Jeff A. Sloan, Charles L. Loprinzi, Gamini S. Soori, Daniel A. Nikcevich, David O. Warner, Paul J. Novotny, Leila A. Kutteh, Gilbert Y. Wong, (unknown)	289
4	Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52 2006 ·Breast Cancer Research and Treatment ·James N. Ingle, Vera J. Suman, James A. Mailliard, John W. Kugler, James E. Krook, John C. Michalak, Thomas M. Pisansky, Lester E. Wold, John H. Donohue, Matthew P. Goetz, Edith A. Perez	37
5	Phase III Trial of Carmustine and Cisplatin Compared With Carmustine Alone and Standard Radiation Therapy or Accelerated Radiation Therapy in Patients With Glioblastoma Multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials 2006 ·Journal of Clinical Oncology ·Jan C. Buckner, Karla V. Ballman, John C. Michalak, Gary V. Burton, Terrence L. Cascino, Paula J. Schomberg, Roland B. Hawkins, Bernd W. Scheithauer, Howard M. Sandler, Randolph S. Marks, Judith R. OʼFallon	69
6	Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients 2005 ·Journal of Neuro-Oncology ·Nicole Marshall, Karla V. Ballman, John C. Michalak, Paula J. Schomberg, Gary V. Burton, Howard M. Sandler, Terrence L. Cascino, Kurt A. Jaeckle, Jan C. Buckner	22
7	Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer 2004 ·Journal of Clinical Oncology ·(unknown), Lawrence J. Burgart, Michelle R. Mahoney, Harold E. Windschitl, Muhammad Salim, Martin Wiesenfeld, James E. Krook, John C. Michalak, Richard M. Goldberg, Michael J. O’Connell, Alfred Furth, Daniel J. Sargent, Linda M. Murphy, (unknown), Darren Riehle, (unknown), Thomas E. Witzig	108
8	Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy 2002 ·Pain ·Julie E. Hammack, John C. Michalak, Charles L. Loprinzi, Jeff A. Sloan, Paul J. Novotny, Gamini S. Soori, Maria Tria Tirona, Kendrith M. Rowland, Philip J. Stella, (unknown)	182
9	Phase III Controlled Evaluation of Glutamine for Decreasing Stomatitis in Patients Receiving Fluorouracil (5-FU)-Based Chemotherapy 1999 ·American Journal of Clinical Oncology ·Scott H. Okuno, (unknown), Charles L. Loprinzi, Jeff A. Sloan, Beth LaVasseur, (unknown), (unknown), (unknown), Larry P. Ebbert, (unknown), John C. Michalak, (unknown)	68
10	Phase II Study of 2-Chlorodeoxyadenosine in Combination With Chlorambucil in Previously Untreated B-Cell Chronic Lymphocytic Leukemia 1999 ·American Journal of Clinical Oncology ·Ayalew Tefferi, Ralph Levitt, Chin‐Yang Li, Georgene Schroeder, Loren K. Tschetter, John C. Michalak, James E. Krook, Thomas E. Witzig	11
11	Lack of Effect of Coumarin in Women with Lymphedema after Treatment for Breast Cancer 1999 ·New England Journal of Medicine ·Charles L. Loprinzi, John W. Kugler, Jeff A. Sloan, Thom W. Rooke, Susan K. Quella, Paul J. Novotny, Rex B. Mowat, John C. Michalak, Philip J. Stella, Ralph Levitt, Loren K. Tschetter, Harold E. Windschitl	121
12	Paclitaxel and G-CSF in Previously Untreated Patients With Extensive Stage Small-Cell Lung Cancer 1999 ·American Journal of Clinical Oncology ·(unknown), Joseph P. Grill, Randolph S. Marks, John W. Kugler, James B. Gerstner, Steven A. Kuross, John C. Michalak, Harold E. Windschitl, (unknown), James R. Jett	48
13	Phase III Clinical Trial of the Combination of Cisplatin, Dacarbazine, and Carmustine With or Without Tamoxifen in Patients With Advanced Malignant Melanoma 1999 ·Journal of Clinical Oncology ·Edward T. Creagan, Vera J. Suman, Robert J. Dalton, Henry C. Pitot, Harry J. Long, Michael H. Veeder, Allen M. Vukov, Kendrith M. Rowland, James E. Krook, John C. Michalak	58
14	Combined Levamisole With Recombinant Interleukin-2 (IL-2) in Patients With Advanced Renal Cell Carcinoma 1998 ·American Journal of Clinical Oncology ·Edward T. Creagan, (unknown), Vera J. Suman, (unknown), Suresh Nair, James E. Krook, John W. Kugler, Robert F. Marschke, John C. Michalak, Loren K. Tschetter	8
15	Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis 1996 ·Cancer ·(unknown), Charles L. Loprinzi, Judith R. OʼFallon, (unknown), (unknown), (unknown), Paul J. Novotny, (unknown), (unknown), John C. Michalak	127
16	Transdermal fentanyl in the management of cancer pain in ambulatory patients: An open-label pilot study 1996 ·Journal of Pain and Symptom Management ·Julie E. Hammack, James A. Mailliard, Charles L. Loprinzi, Raylene M. Rospond, Judith R. OʼFallon, Mary B. Wilwerding, Nicholas F. Reuter, John C. Michalak, (unknown), Angela W. Miser	24
17	Megestrol Acetate for the Prevention of Hot Flashes 1995 ·Obstetrical & Gynecological Survey ·Charles L. Loprinzi, John C. Michalak, Susan K. Quella, Judith R. OʼFallon, Alan K. Hatfield, Robert A. Nelimark, Ann Marie Dose, Tammy Fischer, (unknown), (unknown), (unknown), Raylene M. Rospond, Joseph E. Oesterling	6
18	Phase III Evaluation of 4 Doses of Megestrol Acetate as Therapy for Patients with Cancer Anorexia and/or Cachexia 1994 ·Oncology ·(unknown), Albert M. Bernath, Daniel J. Schaid, (unknown), (unknown), John C. Michalak, Loren K. Tschetter, Alan K. Hatfield, Roscoe F. Morton	44
19	Megestrol Acetate for the Prevention of Hot Flashes 1994 ·New England Journal of Medicine ·Charles L. Loprinzi, John C. Michalak, Susan K. Quella, Judith R. OʼFallon, Alan K. Hatfield, Robert A. Nelimark, Ann Marie Dose, Tammy Fischer, (unknown), (unknown), (unknown), Raylene M. Rospond, Joseph E. Oesterling	371
20	Phase II trial of edatrexate in small cell lung cancer 1994 ·Cancer ·Martin Wiesenfeld, James R. Jett, John Q. Su, (unknown), Carl G. Kardinal, James A. Mailliard, Michael H. Veeder, Roscoe F. Morton, John C. Michalak	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact